# OnCo record nct06016920 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06016920/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06016920", "NCT06016920" ;
  schema:name "Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab in head and neck squamous cell carcinoma, run by Nykode Therapeutics ASA, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06016920/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06016920> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-12-19" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/recurrent-metastatic-hnscc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> .